Last reviewed · How we verify
Sham Control
Sham Control is a placebo comparator used in clinical trials and does not exert any pharmacological effect.
At a glance
| Generic name | Sham Control |
|---|---|
| Sponsor | Kolon TissueGene, Inc. |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Sham Control represents a control arm in clinical studies, typically used to establish baseline efficacy and safety profiles of an investigational therapy. It serves as a comparator to distinguish true drug effects from placebo response and natural disease progression. In the context of Kolon TissueGene's Phase 3 trial, it likely represents a sham procedure or inactive comparator relevant to their tissue engineering or regenerative medicine approach.
Approved indications
Common side effects
Key clinical trials
- Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair (NA)
- The Effects of 5G Radiation on Skin (NA)
- The RECLAIM Study. (NA)
- Alesis OSA-1 Obstructive Sleep Apnea Treatment (NA)
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- Tetris Intervention Following Subliminal Reactivation for Intrusive Memories (NA)
- Effects of Blood Flow Restriction and Small-Sided Games on Soccer Passing and Dribbling Stability Under Fatigue (NA)
- THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sham Control CI brief — competitive landscape report
- Sham Control updates RSS · CI watch RSS
- Kolon TissueGene, Inc. portfolio CI